Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study
ESC Heart Failure · 2026
DOI: 10.1093/eschf/xvaf013 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2026. Verfasst von Dorien Laenens und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, Netherlands. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Heart Failure, Hospitalization. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
Data on the impact of a heart failure hospitalization (HFH) on outcome in patients with transthyretin cardiac amyloidosis (TTR-CA) are scarce, although it remains a frequent adverse event. To assess the characteristics of patients with HFH in a real-world TTR-CA population, the occurrence of HFH, and the prognosis thereafter.
Methods
Data were collected from a multicentre TTR-CA registry and patients were dichotomized according to the occurrence of at least one HFH. Landmark analysis at the 1-year follow-up and Cox regression analysis with HFH as a time-dependent covariate were performed to assess the impact of HFH on all-cause mortality.
Results
Overall, 654 patients were included [median age 78 (64, 83) years, 70.5% male, 70.6% wild type]. During a median follow-up of 24 (11–45) months, 141 (22%) patients experienced at least one HFH and 170 (26%) patients died. Patients with a HFH were older (82 vs 76 years, P < .001), had more wild-type TTR-CA [126 (89.4%) vs 336 (65.5%), P < .001], were more symptomatic [New York Heart Association Class II–IV 119 (86.9%) vs 279 (62%), P < .001], had higher National Amyloidosis Centre (NAC) disease stage, were less treated with disease-modifying therapy [45 (31.9%) vs 247 (47.4%), P = .001], had more co-morbidities and showed signs of more advanced disease by echocardiography. At the 1-year time point, patients with HFH had significant worse overall survival (log-rank χ² 37.673, P < .001). At the univariable (HR 7.71, 95%CI 5.50, 10.82; P < .001) and multivariable analyses, HFH was associated with all-cause mortality and showed incremental value on top of clinical variables, biomarkers [estimated glomerular filtration rate in Model 1 (χ² 97.3; P < .001) and NAC disease stage in Model 2 (χ² 78.8; P < .001)] and echocardiographic parameters (left ventricular mass index + stroke volume index + significant valvular lesion in Model 3 (χ² 60.3; P < .001) and including E/e′ in Model 4 (χ² 43.4; P < .001)).
Conclusion
HFH is independently associated with all-cause mortality in patients with TTR-CA and has incremental value on top of established risk models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, Netherlands.
- Department of Cardiology, Sint Maarten Hospital, Mechelen, Belgium.
- Department of Cardiology, Sint Jan Hospital, Bruges, Belgium.
- Department of Cardiology, ULSSM, CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
- Faculty of Medicine and Life Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
- Department of Cardiology, University Hospital Brussels, Brussels, Belgium.
ORCID-Profile: Dorien Laenens, Philippe Debonnaire, Steven Droogmans, Erwan Donal, Philippe Bertrand, Ruxandra Jurcut, Nina Ajmone Marsan
Zitieren
APA
Laenens, D., Debonnaire, P., De Smet, M. A. J., Pinto, F., Brito, D., Droogmans, S., Verbrugge, F. H., Donal, E., Van de Veire, N., Bertrand, P., Sia, C. H., Ng, A. C. T., Nabeta, T., Sturkenboom, N., Yedidya, I., Jurcut, R., Bax, J. J., & Ajmone Marsan, N. (2026). Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study. ESC Heart Failure. https://doi.org/10.1093/eschf/xvaf013
Vancouver
Laenens D, Debonnaire P, De Smet MAJ, Pinto F, Brito D, Droogmans S, et al. Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study. ESC Heart Failure. 2026. doi:10.1093/eschf/xvaf013
BibTeX
@article{Laenens2026,
author = {Laenens, Dorien and Debonnaire, Philippe and De Smet, Maarten A J and Pinto, Fausto and Brito, Dulce and Droogmans, Steven and Verbrugge, Frederik H and Donal, Erwan and Van de Veire, Nico and Bertrand, Philippe and Sia, Ching Hui and Ng, Arnold C T and Nabeta, Takeru and Sturkenboom, Nicole and Yedidya, Idit and Jurcut, Ruxandra and Bax, Jeroen J and Ajmone Marsan, Nina},
title = {Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study},
journal = {ESC Heart Failure},
year = {2026},
doi = {10.1093/eschf/xvaf013}
}
EUVIMED